Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 4/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3538509 | 1.00 | CDK9 (0.46) | CDK9CCNT1CHRNB2CHRNA4CHRNA7 | |
| Cadaverine Tartrate SCHEMBL3538150 | 0.89 | CCNT1 (0.39) | CDK9CCNT1CHRNB2CHRNA4CHRNA7 | |
| Cadaverine Tartrate SCHEMBL3538152 | 0.89 | CCNT1 (0.39) | CDK9CCNT1CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL3539509 | 0.85 | CHRNB2 (0.44) | CDK9CCNT1CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL3539511 | 0.85 | CHRNB2 (0.44) | CDK9CCNT1CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL2412726 | 0.80 | CHRNB2 (0.47) | CDK9CCNT1CHRNB2CHRNA4 | |
| SCHEMBL2413769 | 0.72 | CHRNB2 (0.41) | CDK9CCNT1CHRNB2CHRNA4P2RY14 | |
| SCHEMBL2413772 | 0.72 | CHRNB2 (0.41) | CDK9CCNT1CHRNB2CHRNA4P2RY14 | |
| SCHEMBL3538066 | 0.72 | SLC6A2 (0.49) | CHRNA7HTR3A | |
| SCHEMBL3538063 | 0.72 | SLC6A2 (0.49) | CHRNA7HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781456-B2 | Enantiomers of 3-heteroaryl-8H-8-azabicyclo(3.2.1)oct-2-ene and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2010-08-24 | — | — | US | claimed |
| US-20080214820-A1 | Enantiomers of 3-Heteroaryl-8H-8-Azabicyclo (3.2.1) Oct-2-Ene and their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2008-09-04 | — | — | US | claimed |
| US-7781456-B2 | Enantiomers of 3-heteroaryl-8H-8-azabicyclo(3.2.1)oct-2-ene and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2010-08-24 | — | — | US | disclosed |
| US-20080214820-A1 | Enantiomers of 3-Heteroaryl-8H-8-Azabicyclo (3.2.1) Oct-2-Ene and their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214820-A1 | Enantiomers of 3-Heteroaryl-8H-8-Azabicyclo (3.2.1) Oct-2-Ene and their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC18A3 | CDK9 1844/4885CCNT1 1918/4885CHRNB2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.